The U.S. Food and Drug Administration (FDA) has authorized an updated indication for BRAVECTO QUANTUM (fluralaner for extended-release injectable suspension), a product from Merck Animal Health. The expanded label includes treatment and control of the Asian longhorned tick (H. longicornis) and the Gulf Coast tick (A. maculatum) for 12 months following a single injection administered by a veterinarian. Originally approved in July 2025, the injectable formulation is indicated to kill adult fleas and control several tick species, including black-legged, American dog, and brown dog ticks for 12 months, and lone star ticks for eight months. The update reflects concerns over the geographic spread of certain tick species and associated disease risks, and aims to help veterinarians and pet owners improve compliance with a once-yearly approach. For more information, visit the Merck Animal Health website.
